

Cristina R Ferrone

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5408446/cristina-r-ferrone-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

184
papers

7,877
citations

42
h-index

86
g-index

201
ext. papers

10,503
ext. citations

5.8
avg, IF

5.67
L-index

#	Paper	IF	Citations
184	Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. <i>Science</i> , 2017 , 357, 1156-1160	33.3	577
183	Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. <i>Annals of Surgery</i> , 2015 , 261, 12-7	7.8	544
182	Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. <i>Nature</i> , 2015 , 524, 361-5	50.4	475
181	Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. <i>Cell Reports</i> , 2014 , 8, 1905-1918	10.6	339
180	Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?. <i>Annals of Surgery</i> , 2013 , 257, 731-6	7.8	295
179	Mutant IDH inhibits HNF-4 α to block hepatocyte differentiation and promote biliary cancer. <i>Nature</i> , 2014 , 513, 110-4	50.4	288
178	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 460-8	2.2	257
177	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 963-969	13.4	253
176	Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy. <i>Cancer Discovery</i> , 2016 , 6, 852-69	24.4	213
175	FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. <i>Oncologist</i> , 2013 , 18, 543-8	5.7	213
174	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. <i>Cell</i> , 2019 , 178, 160-175.e27	56.2	211
173	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2019 , 5, 1020-1027	13.4	205
172	Pancreatic fistula rates after 462 distal pancreatectomies: staplers do not decrease fistula rates. <i>Journal of Gastrointestinal Surgery</i> , 2008 , 12, 1691-7; discussion 1697-8	3.3	194
171	Pancreatic Adenocarcinoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 202-210	7.3	179
170	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019 , 9, 1064-1079	24.4	154
169	Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. <i>Surgery</i> , 2012 , 152, S43-9	3.6	154
168	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. <i>Annals of Surgery</i> , 2019 , 269, 733-740	7.8	151

167	Current trends in pancreatic cystic neoplasms. <i>Archives of Surgery</i> , 2009 , 144, 448-54		126
166	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 470-8	12.9	124
165	Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center. <i>Gastroenterology</i> , 2017 , 153, 1284-1294.e1	13.3	119
164	Effects of Intraoperative Fluid Management on Postoperative Outcomes: A Hospital Registry Study. <i>Annals of Surgery</i> , 2018 , 267, 1084-1092	7.8	110
163	Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 439-457	7.3	103
162	Twenty-three years of the Warshaw operation for distal pancreatectomy with preservation of the spleen. <i>Annals of Surgery</i> , 2011 , 253, 1136-9	7.8	98
161	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2016 , 6, 727-39	24.4	94
160	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015 , 20, 1019-27	5.7	88
159	Benchmarks in Pancreatic Surgery: A Novel Tool for Unbiased Outcome Comparisons. <i>Annals of Surgery</i> , 2019 , 270, 211-218	7.8	82
158	A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 830-8	4	81
157	HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. <i>Neoplasia</i> , 2014 , 16, 31-42	6.4	72
156	Understanding hospital readmissions after pancreaticoduodenectomy: can we prevent them?: a 10-year contemporary experience with 1,173 patients at the Massachusetts General Hospital. <i>Journal of Gastrointestinal Surgery</i> , 2014 , 18, 137-44; discussion 144-5	3.3	67
155	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. <i>Annals of Surgery</i> , 2018 , 267, 157-163	7.8	66
154	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 64-72	4	64
153	Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. <i>JAMA Surgery</i> , 2018 , 153, 809-815	5.4	62
152	The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer. <i>Surgery</i> , 2015 , 157, 881-7	3.6	61
151	Discordance Between Perioperative Antibiotic Prophylaxis and Wound Infection Cultures in Patients Undergoing Pancreaticoduodenectomy. <i>JAMA Surgery</i> , 2016 , 151, 432-9	5.4	60
150	The Ability to Diagnose Intrahepatic Cholangiocarcinoma Definitively Using Novel Branched DNA-Enhanced Albumin RNA In Situ Hybridization Technology. <i>Annals of Surgical Oncology</i> , 2016 , 23, 290-6	3.1	58

149	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	53
148	Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. <i>Surgery</i> , 2014 , 156, 611-21	3.6	53
147	Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. <i>Cancer</i> , 2013 , 119, 4196-204	6.4	48
146	Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. <i>Journal of the American College of Surgeons</i> , 2015 , 220, 839-44	4.4	46
145	Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. <i>Liver Cancer</i> , 2017 , 6, 360-374	9.1	44
144	Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016 , 23, 181-7	2.8	44
143	B7-H3: An Attractive Target for Antibody-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 1227-1235	10.35	44
142	Defective HLA class I antigen processing machinery in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 999-1009	7.4	42
141	Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care?. <i>Journal of the American College of Surgeons</i> , 2015 , 221, 1015-22	4.4	38
140	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 5586-5594	12.9	37
139	Role of Tumor-Associated Macrophages in the Clinical Course of Pancreatic Neuroendocrine Tumors (PanNETs). <i>Clinical Cancer Research</i> , 2019 , 25, 2644-2655	12.9	34
138	Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 ,	11.5	34
137	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. <i>Cancer Letters</i> , 2017 , 409, 9-19	9.9	33
136	Number of Examined Lymph Nodes and Nodal Status Assessment in Distal Pancreatectomy for Body/Tail Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2019 , 270, 1138-1146	7.8	33
135	Acute pancreatitis in intraductal papillary mucinous neoplasms: A common predictor of malignant intestinal subtype. <i>Surgery</i> , 2015 , 158, 1219-25	3.6	32
134	Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 4020-4026	3.1	30
133	Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 277-83	3.3	28
132	A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. <i>Biomaterials</i> , 2016 , 93, 71-82	15.6	27

131	Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. <i>Nuclear Medicine and Biology</i> , 2018 , 58, 67-73	2.1	26
130	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Annals of Surgery</i> , 2018 , 268, 340-347	7.8	26
129	Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift. <i>Frontiers in Oncology</i> , 2019 , 9, 1085	5.3	26
128	Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. <i>Surgery</i> , 2017 , 162, 203-210	3.6	25
127	Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. <i>DMM Disease Models and Mechanisms</i> , 2018 , 11,	4.1	25
126	Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions. <i>Gastroenterology</i> , 2019 , 157, 720-730.e2	13.3	25
125	Reappraisal of Staging Laparoscopy for Patients with Pancreatic Adenocarcinoma: A Contemporary Analysis of 1001 Patients. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3203-3211	3.1	24
124	Staging Laparoscopy Not Only Saves Patients an Incision, But May Also Help Them Live Longer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 1009-1016	3.1	23
123	Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2017 , 116, 658-664	2.8	21
122	Diabetes mellitus in intraductal papillary mucinous neoplasm of the pancreas is associated with high-grade dysplasia and invasive carcinoma. <i>Pancreatology</i> , 2017 , 17, 920-926	3.8	21
121	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014 , 110, 160-4	5.3	21
120	"Idealized" vs. "True" learning curves: the case of laparoscopic liver resection. <i>Hpb</i> , 2016 , 18, 504-9	3.8	21
119	Pancreatic neuroendocrine tumor: Correlations between MRI features, tumor biology, and clinical outcome after surgery. <i>Journal of Magnetic Resonance Imaging</i> , 2018 , 47, 425-432	5.6	20
118	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 1871-1884	8.8	20
117	Randomized trial of a perioperative geriatric intervention for older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 12012-12012	2.2	19
116	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020 ,	7.8	18
115	Acinar cell cystadenoma: A challenging cytology diagnosis, facilitated by moray micro-forceps biopsy. <i>Diagnostic Cytopathology</i> , 2017 , 45, 557-560	1.4	17
114	Clinical impact of PET/MR in treated colorectal cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 2260-2269	8.8	17

113	Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 37646-37656	3.3	17
112	Revision of Pancreatic Neck Margins Based on Intraoperative Frozen Section Analysis Is Associated With Improved Survival in Patients Undergoing Pancreatectomy for Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2021 , 274, e134-e142	7.8	17
111	Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2016 , 23, 609-617	3.1	16
110	Hepatocellular carcinoma surgical therapy: perspectives on the current limits to resection. <i>Chinese Clinical Oncology</i> , 2018 , 7, 48	2.3	15
109	Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019 , 26, 4091-4099	3.1	14
108	Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. <i>Molecular Oncology</i> , 2015 , 9, 1982-93	7.9	14
107	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020 , 272, 731-737	7.8	14
106	Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer. <i>JCI Insight</i> , 2017 , 2, e91078	9.9	13
105	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. <i>Clinical Cancer Research</i> , 2020 , 26, 5007-5018	12.9	11
104	Spectrum and Classification of Cystic Neoplasms of the Pancreas. <i>Surgical Oncology Clinics of North America</i> , 2016 , 25, 339-50	2.7	11
103	TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 386-386	2.2	11
102	Reappraising the Concept of Conditional Survival After Pancreatectomy for Ductal Adenocarcinoma: A Bi-institutional Analysis. <i>Annals of Surgery</i> , 2020 , 271, 1148-1155	7.8	11
101	Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study. <i>Annals of Surgery</i> , 2021 , 274, e980-e987	7.8	11
100	Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 182-191	9.7	11
99	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. <i>Practical Radiation Oncology</i> , 2018 , 8, 414-421	2.8	11
98	Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. <i>American Journal of Surgery</i> , 2019 , 218, 959-966	2.7	10
97	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2017 , 21, 1831-1840	3.3	10
96	Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges. <i>Chinese Clinical Oncology</i> , 2016 , 5, 9	2.3	10

95	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 953-9	3.3	10
94	Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. <i>Journal of the American College of Surgeons</i> , 2021 , 232, 361-371	4.4	10
93	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2018 , 25, 4027-4034	3.1	10
92	Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 656-661	2.7	9
91	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1122-1129	3.1	9
90	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. <i>Oncologist</i> , 2019 , 24, 945-954	5.7	9
89	Cholangiolar pattern and albumin in situ hybridisation enable a diagnosis of intrahepatic cholangiocarcinoma. <i>Journal of Clinical Pathology</i> , 2020 , 73, 23-29	3.9	9
88	Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. <i>American Journal of Surgery</i> , 2020 , 220, 29-34	2.7	8
87	Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. <i>Seminars in Oncology</i> , 2014 , 41, 685-99	5.5	8
86	Primary lymph node gastrinoma: A single institution experience. <i>Surgery</i> , 2017 , 162, 1088-1094	3.6	8
85	Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4116-4116	2.2	8
84	Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1400-1406	3.1	8
83	Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. <i>Molecular Imaging and Biology</i> , 2021 , 23, 456-466	3.8	8
82	Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma?. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3936-3942	3.1	8
81	Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018 , 18, 166-181	2.2	7
80	Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. <i>American Journal of Surgery</i> , 2019 , 218, 157-163	2.7	7
79	Simulated Volume-Based Regionalization of Complex Procedures: Impact on Spatial Access to Care. <i>Annals of Surgery</i> , 2021 , 274, 312-318	7.8	6
78	Does Site Matter? Impact of Tumor Location on Pathologic Characteristics, Recurrence, and Survival of Resected Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3898-3912	3.1	6

77	Mutant-IDH inhibits Interferon-TET2 signaling to promote immunoevasion and tumor maintenance in cholangiocarcinoma. <i>Cancer Discovery</i> , 2021 ,	24.4	5
76	Lymphoepithelial cysts and cystic lymphangiomas: Under-recognized benign cystic lesions of the pancreas. <i>World Journal of Gastrointestinal Surgery</i> , 2014 , 6, 136-41	2.4	5
75	Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1606-1612 ^{3.1}		5
74	Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. <i>Histopathology</i> , 2020 , 77, 35-45	7.3	4
73	Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. <i>Pancreatology</i> , 2020 , 20, 691-697	3.8	4
72	Hospital readmission after distal pancreatectomy is predicted by specific intra- and post-operative factors. <i>American Journal of Surgery</i> , 2018 , 216, 511-517	2.7	4
71	Primary Hepatic Gastrinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016 , 20, 662-3	3.3	4
70	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. <i>Practical Radiation Oncology</i> , 2014 , 4, e117-e123	2.8	4
69	Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2020 ,	7.8	4
68	Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4118-4118	2.2	4
67	Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma. <i>Advances in Surgery</i> , 2016 , 50, 115-28.2		4
66	Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation. <i>Hpb</i> , 2019 , 21, 834-840	3.8	4
65	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. <i>Annals of Surgery</i> , 2021 , 274, 721-728	7.8	4
64	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.. <i>Cancer Discovery</i> , 2022 , OF1-OF18	24.4	4
63	Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. <i>American Journal of Surgery</i> , 2020 , 220, 1579-1585	2.7	3
62	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020 , 18, 255	8.5	3
61	Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. <i>Histopathology</i> , 2020 , 77, 144-155	7.3	3
60	Using circulating tumor DNA (ctDNA) to predict surgical outcome after neoadjuvant chemoradiation for locally advanced pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 272-272	2.2	3

59	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3773-3777	2.2	3
58	Does preoperative pharmacologic prophylaxis reduce the rate of venous thromboembolism in pancreatectomy patients?. <i>Hpb</i> , 2020 , 22, 1020-1024	3.8	3
57	Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 567289	5.3	3
56	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5161-5172	3.1	3
55	Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 1727-1735	3.3	3
54	Assessment of the Long-Term Impact of Pancreatoduodenectomy on Health-Related Quality of Life Using the EORTC QLQ-PAN26 Module. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4216-4224	3.1	3
53	Clinical impact of PET/MRI in oligometastatic colorectal cancer. <i>British Journal of Cancer</i> , 2021 , 125, 975-982	3	3
52	Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 1135-1142	3.3	3
51	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes. <i>Pancreatology</i> , 2021 ,	3.8	3
50	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. <i>Modern Pathology</i> , 2019 , 32, 844-854	9.8	2
49	Diagnosis of Depression is Associated with Readmission Following Elective Pancreatectomy. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4544-4550	3.1	2
48	Socioeconomic determinants of the surgical treatment of colorectal liver metastases. <i>American Journal of Surgery</i> , 2020 , 220, 952-957	2.7	2
47	Late Pancreatic Fistula After Pancreaticoduodenectomy: A Case Report and Review of the Literature. <i>Case Reports in Pancreatic Cancer</i> , 2016 , 2, 65-70		2
46	After Neoadjuvant Therapy, Imaging No Longer Provides a Clear Answer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 300	4	2
45	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 230-230	2.2	2
44	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020 , 10, e183-e187	2.8	2
43	Preoperative cholangitis is an independent risk factor for mortality in patients after pancreaticoduodenectomy for pancreatic cancer. <i>American Journal of Surgery</i> , 2021 , 221, 134-140	2.7	2
42	Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. <i>Journal of Surgical Research</i> , 2021 , 259, 253-260	2.5	2

41	CT and MRI features differentiating mucinous cystic neoplasms of the liver from pathologically simple cysts. <i>Clinical Imaging</i> , 2021 , 76, 46-52	2.7	2
40	Neoadjuvant Chemotherapy in Pancreatic Cancer 2018 , 1187-1202		1
39	Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. <i>Advances in Surgery</i> , 2019 , 53, 253-269	1.2	1
38	In response to Birgir Gudjonsson, MD. <i>Surgery</i> , 2014 , 156, 1286	3.6	1
37	Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4128-4128	2.2	1
36	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4020-4020	2.2	1
35	Intraoperative radiotherapy (IORT) in the era of intensive neoadjuvant chemotherapy and chemoradiotherapy for locally advanced and borderline resectable adenocarcinoma of the pancreas (PDAC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 393-393	2.2	1
34	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer (BRPC): Toxicity, R0 resection, and interim survival data from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4113-4113	2.2	1
33	FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 368-368	2.2	1
32	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 412-412	2.2	1
31	Outcomes following liver SBRT for metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 418-418	2.2	1
30	Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 392-392 ^{2.2}	2.2	1
29	Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognostic determinants and identifying therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 210-210	2.2	1
28	Analysis of in court malpractice litigation following pancreatic surgery. <i>Pancreatology</i> , 2021 , 21, 819-823 ^{3.8}		1
27	Promoting Women in Academic Medicine during COVID-19 and Beyond. <i>Journal of General Internal Medicine</i> , 2021 , 36, 3292-3294	4	1
26	Patient and Caregiver Considerations and Priorities When Selecting Hospitals for Complex Cancer Care. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4183-4192	3.1	1
25	The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 429-429	2.2	1
24	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.. <i>JAMA Oncology</i> , 2021 ,	13.4	1

23	Differential role of HLA-A and HLA-B, C expression levels as prognostic markers in colon and rectal cancer. 2022 , 10,		1
22	Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. <i>European Radiology</i> , 2021 , 1	8	0
21	Effects of laparoscopic vs open abdominal surgery on costs and hospital readmission rate and its effect modification by surgeons' case volume. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020 , 34, 1-12	5.2	0
20	Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. <i>Surgical Oncology Clinics of North America</i> , 2019 , 28, 745-762	2.7	0
19	A multi-institutional study of patient-derived gender-based discrimination experienced by resident physicians. <i>American Journal of Surgery</i> , 2021 , 221, 309-314	2.7	0
18	Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 25, 2859-2870	3.3	0
17	Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4592-4601	3.1	0
16	Fibrohistiocytic Variant of Hepatic Pseudotumor: An Antibiotic Responsive Tumefactive Lesion. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1314-1323	6.7	0
15	Endovascular diagnosis of radiographically and intraoperatively occult insulinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015 , 26, 760-2	2.4	
14	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 159-159	2.2	
13	Patient-reported outcomes (PROs) in older adults with gastrointestinal (GI) cancer undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e24032-e24032	2.2	
12	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 376-376	2.2	
11	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4117-4117	2.2	
10	Phase I/II study of preoperative (pre-op) short course chemoradiation (CRT) with proton beam therapy (PBT) and capecitabine (cape) followed by early surgery for resectable pancreatic ductal adenocarcinoma (PDAC) of the head.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4021-4021	2.2	
9	Reply to G.W. Peters et al and S. Shi et al. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2947-2948	2.2	
8	ASO Author Reflections: Long-Term Impact of Pancreatoduodenectomy on Pancreas-Specific Quality of Life. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4225-4226	3.1	
7	Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4133-4133	2.2	
6	Pancreatic acinar cell carcinoma: A multi-center series on clinical characteristics and treatment outcomes.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16253-e16253	2.2	

- 5 A Rare Case of Gallbladder Small Cell Carcinoma. *Journal of Gastrointestinal Surgery*, **2021**, 25, 561-564 3.3
- 4 Prognostic impact of chemoradiation-related lymphopenia in patients with locally advanced pancreatic cancer.. *Journal of Clinical Oncology*, **2021**, 39, 439-439 2.2
- 3 ASO Author Reflections: Staging Laparoscopy Improves Overall Survival of Patients with Pancreatic Adenocarcinoma Found to Have Occult Metastatic Disease. *Annals of Surgical Oncology*, **2018**, 25, 830-833¹
- 2 Which Patient Do I Attend to First? Night-float Simulation to Assess Surgical Interns' Clinical Prioritization Skills. *Journal of Surgical Education*, **2021**, 78, e226-e231 3.4
- 1 Open hepatic resection in the elderly at two tertiary referral centers. *American Journal of Surgery*, **2021**, 222, 594-598 2.7